Photodynamic therapy and its role in combined modality anticancer treatment

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Photodynamic therapy (PDT) is a relatively new modality for anticancer treatment and although the interest has increased greatly in the recent years, it is still far from clinical routine. As PDT consists of administering a nontoxic photosensitizing chemical and subsequently illuminating the tumor with visible light, the treatment is not subject to dose-limiting toxicity, which is the case for established anticancer treatments like radiation therapy or chemotherapy. This makes PDT an attractive adjuvant therapy in a combined modality treatment regimen, as PDT provides an antitumor immune response through its ability to elicit the release of damage-associated molecular patterns and tumor antigens, thus providing an increased antitumor efficacy, potentially without increasing the risk of treatment-related toxicity. There is great interest in the elicited immune response after PDT and the potential of combining PDT with other forms of treatment to provide potent antitumor vaccines. This review summarizes recent studies investigating PDT as part of combined modality treatment, hopefully providing an accessible overview of the current knowledge that may act as a basis for new ideas or systematic evaluations of already promising results.

Original languageEnglish (US)
Pages (from-to)355-368
Number of pages14
JournalTechnology in Cancer Research and Treatment
Issue number4
StatePublished - Jan 1 2015


  • Cancer
  • Combined-modality treatment
  • Immunogenicity
  • Photodynamic therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Photodynamic therapy and its role in combined modality anticancer treatment'. Together they form a unique fingerprint.

Cite this